immediate sequential bilateral intravitreal injections: an indian perspective

Koushik Tripathy Department of Vitreoretina and Uvea, ICARE Eye Hospital and Postgraduate Institute, Sector-26, Noida, Uttar Pradesh, IndiaRecently, Ruão et al1 have shown in a study spanning 6 years that only 1 of 6560 (0.015%) eyes undergoing unilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection developed culture-proven endophthalmitis. None of the 1612 eyes receiving immediate sequential bilateral intravitreal treatment (ISBIVT) with anti-VEGF injection developed endophthalmitis.1 Likewise, immediate sequential bilateral cataract surgery (ISBCS)2 has been proposed to provide “potentially decreased wait times for surgery, patient convenience and cost savings for health care payors”, with comparable visual outcomes and complication rates. However, in an Indian scenario, there is need for discussion regarding endophthalmitis following ISBIVT injections.View the original paper by Ruão and colleagues.